|
Antibiotic
|
Total (n = 174)
|
ESBL– (n = 103)
|
ESBL + (n = 71)
|
P-value
|
|---|
|
R No. (%)
|
I No. (%)
|
S No. (%)
|
R No. (%)
|
I No. (%)
|
S No. (%)
|
R No. (%)
|
I No. (%)
|
S No. (%)
|
|---|
|
Cefotaxime
|
77 (44.3)
|
3 (1.7)
|
94 (54.0)
|
7 (6.8)
|
2 (1.9)
|
94 (91.3)
|
70 (98.6)
|
1 (1.4)
|
–
|
< 0.001
|
|
Ceftazidime
|
49 (28.2)
|
20 (11.5)
|
105 (60.3)
|
5 (4.9)
|
3 (2.9)
|
95 (92.2)
|
44 (62.0)
|
17 (23.9)
|
10 (14.1)
|
< 0.001
|
|
Piperacillin-tazo
|
1 (0.6)
|
11 (6.3)
|
162 (93.1)
|
–
|
5 (4.9)
|
98 (95.1)
|
1 (1.4)
|
6 (8.2)
|
64 (90.1)
|
0.298
|
|
Ertapenem
|
1 (0.6)
|
–
|
173 (99.4)
|
1 (1.0)
|
–
|
102 (99.0)
|
–
|
–
|
71 (100)
|
0.405
|
|
Imipenem
|
–
|
1 (0.6)
|
173 (99.4)
|
–
|
1 (1.0)
|
102 (99.0)
|
–
|
–
|
71 (100)
|
0.405
|
|
Ciprofloxacin
|
44 (25.3)
|
10 (5.74)
|
120 (69.0)
|
14 (13.6)
|
4 (3.9)
|
85 (82.5)
|
30 (42.4)
|
6 (8.2)
|
35 (49.4)
|
< 0.001
|
|
Levofloxacin
|
42 (24.1)
|
3 (1.7)
|
129 (74.2)
|
10 (9.7)
|
2 (1.94)
|
91 (88. 4)
|
32 (45.1)
|
1 (1.4)
|
38 (53.5)
|
< 0.001
|
|
Amikacin
|
1 (0.6)
|
6 (3.4)
|
167 (96.0)
|
–
|
3 (2.9)
|
100 (97.1)
|
1 (1.4)
|
3 (4.2)
|
67 (94.4)
|
0.429
|
|
Tetracyclines
|
100 (57.5)
|
4 (2.3)
|
70 (40.2)
|
44 (42.7)
|
3 (2.9)
|
56 (54.4)
|
56 (78.9)
|
1 (1.4)
|
14 (19.7)
|
< 0.001
|
|
Ampicillin
|
119 (68.4)
|
5 (2.9)
|
50 (28.7)
|
49 (47.6)
|
5 (4.9)
|
49 (47.6)
|
70 (98.6)
|
–
|
1 (1.4)
|
< 0.001
|
|
Trimethoprim-sulfa
|
104 (59.8)
|
–
|
70 (40.2)
|
43 (41.7)
|
–
|
60 (58.3)
|
61 (85.9)
|
–
|
10 (14.1)
|
< 0.001
|
- R resistant, I intermediate, S sensitive, ESBL extended spectrum β-lactamase, STEC Shiga toxin‐producing Escherichia coli
